Ravi Singh


Although there has been much progress made in the field of novel antithrombotic treatments in the last two decades, it is known that the current therapies are severely deficient, particularly in terms of toxicity, and the major risk of bleeding. My research aims to use computational modelling and synthetic chemistry to help design inhibitors against a novel target. The analogues synthesized are tested in a chromogenic assay, which is ran by colleagues at the Leeds Institute of Cardiology and Metabolic Medicine (LICAMM) based here in the University of Leeds.

Poster Prize Winner (1st) at the School of Chemistry Postgraduate Conference in June 2017 (Leeds).

Began PhD in October 2015 with Dr Richard Foster (School of Chemistry, University of Leeds). Co-supervised by Professor Colin Fishwick (School of Chemistry, University of Leeds), Professor Robert Ariens (LICAMM, University of Leeds) and Professor Helen Phillipou (LICAMM, University of Leeds).

Received MChem and BSc (Hons) from University of Leeds in 2015 in Medicinal Chemistry.

Research interests

  • Medicinal Chemistry
  • Chemical Biology
  • Organic Synthesis


  • MChem (University of Leeds)
  • BSc (Universty of Leeds)